Morgan Stanley 22 nd Annual Global Healthcare Conference on September 4 in New York 2024 Wells Fargo Healthcare Conference on September 5 in Boston SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at two upcoming investor conferences in September.
Chief Executive Officer Kevin Gorman , Chief Business Development and Strategy Officer Kyle Gano , and Chief Financial Officer Matt Abernethy will present at the Morgan Stanley 22 nd Annual Global Healthcare Conference in New York at 3:20 p.m. Eastern Time on Wednesday , September 4, 2024.
Kyle Gano and Matt Abernethy will present at the 2024 Wells Fargo Healthcare Conference in Boston at 8:45 a.m. Eastern Time on Thursday , September 5, 2024.
The live presentations will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com .
A replay of the webcasts will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month. About Neurocrine Biosciences Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders.
The company's diverse portfolio includes FDA-approved treatments for tardive dyskin.